# Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression

> **NCT00042575** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 120 (—)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Duloxetine

## Key facts

- **NCT ID:** NCT00042575
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** —
- **Final completion:** 2002-08
- **Target enrollment:** 120 (—)
- **Last updated:** 2006-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042575, "Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00042575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*